GEODE CAPITAL MANAGEMENT, LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$37,764,558
+112.2%
1,269,674
+28.6%
0.00%
+100.0%
Q2 2023$17,794,575
+16.0%
987,490
+3.4%
0.00%0.0%
Q1 2023$15,335,057
+90866.1%
954,860
+3.7%
0.00%0.0%
Q4 2022$16,858
-99.9%
921,230
+4.3%
0.00%
-33.3%
Q3 2022$17,343,000
+9.3%
883,095
+3.8%
0.00%
+50.0%
Q2 2022$15,869,000
-2.4%
850,938
+14.9%
0.00%0.0%
Q1 2022$16,251,000
-18.1%
740,385
+6.0%
0.00%0.0%
Q4 2021$19,851,000
+81.4%
698,738
+34.4%
0.00%
+100.0%
Q3 2021$10,945,000
+14.1%
519,997
+2.2%
0.00%0.0%
Q2 2021$9,591,000
+66.3%
508,821
+34.8%
0.00%0.0%
Q1 2021$5,767,000
+27.1%
377,434
+17.4%
0.00%0.0%
Q4 2020$4,536,000
-7.1%
321,501
+3.1%
0.00%0.0%
Q3 2020$4,885,000
-11.9%
311,777
-1.5%
0.00%0.0%
Q2 2020$5,545,000
+181.5%
316,560
+136.2%
0.00%0.0%
Q1 2020$1,970,000
-69.4%
134,019
-47.8%
0.00%0.0%
Q4 2019$6,442,000
+252.0%
256,818
+111.1%
0.00%
Q3 2019$1,830,000
-38.8%
121,678
+1.8%
0.00%
-100.0%
Q2 2019$2,988,000
+45.6%
119,535
+32.5%
0.00%0.0%
Q1 2019$2,052,000
-54.8%
90,192
-40.4%
0.00%0.0%
Q4 2018$4,536,000
+163.4%
151,306
+151.7%
0.00%
Q3 2018$1,722,00060,1150.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders